News

Dr. Smith’s Diaper Rash Ointment

BY DSN STAFF

-ADVERTORIAL-

Dr. Smith's® Diaper Rash Ointment Now Available Nationwide at Leading Drug Stores, Grocers and Supercenters

Mission Pharmacal, maker of Dr. Smith's® Diaper Rash Ointment, announced it is expanding distribution to make the product readily available to more parents across the country. Dr. Smith's Diaper Rash Ointment can now be found at more than 10,000 new retail locations, including Walgreens (and Walgreens.com), Kroger and many Walmart stores. A trusted and popular product, Dr. Smith's is pediatrician-developed and pharmacists have recommended it to generations of parents. It's already familiar to shoppers at Albertson's, H-E-B, Publix, Harris Teeter, Ingles, Schnucks and numerous other leading regional retailers. Mission Pharmacal is proud to expand its reach to help more families. The ointment can also be purchased online at Amazon.com and Drugstore.com.

For more information, visit the website.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA approves Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease

BY Michael Johnsen

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease, a rare disorder similar to lymphoma (cancer of the lymph nodes).

MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body. The disease usually affects adults who often suffer from fever, night sweats, weight loss and weakness or fatigue because their body’s immune system is weakened and cannot fight infections.

Sylvant is an injection that works by blocking a protein that stimulates abnormal growth of immune cells. It is intended for patients with MCD who do not have HIV or human herpes virus 8 (HHV-8).

“Sylvant is the first FDA-approved drug to treat patients with MCD,” stated Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval demonstrates the FDA’s commitment to approving drugs for rare diseases.”

The FDA reviewed Sylvant under its priority review program, which provides an expedited review for drugs that demonstrate the potential to be a significant improvement in safety or effectiveness in the treatment of a serious condition. Sylvant was also granted orphan product designation because it is intended to treat a rare disease or condition.

Sylvant’s safety and effectiveness were evaluated in a clinical trial of 79 participants with MCD who were HIV and HHV-8 negative. Participants were randomly assigned to receive a combination of Sylvant and best supportive care, or placebo and best supportive care. Results showed 34% of participants treated with Sylvant and best supportive care experienced tumor response, while no participant treated with placebo and best supportive care did.

Common side effects include itchy skin (pruritis), weight gain, rash, increased levels of uric acid in the blood and upper respiratory tract infection.

Sylvant is marketed by Janssen Biotech, based in Horsham, Pa.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Safeway Q1 sales up 1%

BY Michael Johnsen

PLEASANTON, Calif. — Safeway on Wednesday afternoon posted sales of $8.3 billion in the first quarter of 2014, representing an increase of 1%. The slight uptick in sales was primarily attributed to an identical-store sales (excluding fuel) increase of 1.8%, partly offset by lower fuel sales in 2014.

The identical-store sales (excluding fuel) increase of 1.8% consists of a 1% increase in price per item and a 0.8% increase in volume. Safeway's share of sales in all outlet channels increased slightly, and sales to its most loyal households improved during the quarter.

"We are working diligently to close the merger with Albertsons by the fourth quarter," stated Robert Edwards, Safeway president & CEO. "While sales met plan in the first quarter, income was slightly below plan, in part as a result of inflation in produce, meat and pharmacy that was not fully passed along for competitive reasons," he said. "In the second quarter of 2014, identical-stores sales are currently running well above 2%, and we expect to pass along most of the inflation we are experiencing. In addition, the direct and indirect cost initiatives we are implementing are expected to improve profitability in the second half of 2014."

Safeway continues to drive sales momentum through its center of store remodels, as well as merchandising premium, Hispanic and Asian products to meet local demographic needs, Edwards reported. "In addition, our sales of organic and natural products continue to grow at a rapid pace, with our private label brands O Organics and Open Nature growing approximately two times faster than the rest of the market."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?